GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Synergy Pharmaceuticals Inc (SGYP) [hlAlert]

Rating:
Buy SGYP
up 50.00 %

Synergy Pharmaceuticals Inc (SGYP) rated Buy by Citigroup

Posted on: Monday,  Jun 17, 2013  8:25 AM ET by Citigroup

Citigroup rated Buy Synergy Pharmaceuticals Inc (NASDAQ: SGYP) on 06/17/2013, when the stock price was $4.92. Since
then, Synergy Pharmaceuticals Inc has gained 50.00% as of 01/05/2016's recent price of $7.38.
If you would have followed this Citigroup's recommendation on SGYP, you would have gained 50% of your investment in 932 days.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company?s lead drug candidate is SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). SP-304 is an analog of uroguanylin, a natural GI hormone secreted in the gut, which is a key regulator of intestinal function. As of December 31, 2009, the Company was developing SP-304, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. SP-304 is an agonist of GC-C. In February, 2010, a Phase IIa 14-day, repeated-oral-dose trial of SP-304 in CC patients opened for enrollment and was actively recruiting patients.

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/17/2013 8:25 AM Buy
None
4.92
as of 12/13/2013
1 Week down  -3.86 %
1 Month down  -1.16 %
3 Months down  -10.00 %
1 YTD down  -14.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy